Clinically relevant stereochemistry reprograms amyloid proteome for aggregation cross-talk–conferred neuroprotection
Science Advances · 27.03.2026 · 12 (13)
DOI: 10.1126/sciadv.aeb2729 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 27.03.2026. Verfasst von Jiaxin Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Key Laboratory of Biosensing and Molecular Recognition, Research Center for Analytical Science, Frontiers Science Center for New Organic Matt…. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Alzheimer Disease, Proteome, Protein Aggregation, Pathological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, National key R&D program of China.
Abstract (Originalsprache)
The stereochemical diversity of Aβ42 in the brains of patients with Alzheimer’s disease (AD) is a clinically recognized but poorly understood phenomenon. A critical gap in our knowledge is how the complex mixture of these stereoisomers collectively influences the aggregation pathway and neurotoxicity of Aβ42 at the molecular level. Drawing from stereoproteome data from AD patient brain tissues and previous studies, we engineered a panel of stereoisomers to more simply simulate the stereochemical diversity of the AD marker Aβ42. We found that the coexistence of L-Aβ42 with specific D-isomers initiates a potent antagonistic effect, suppressing the formation of toxic fibrils. This stereochemically driven antagonism conferred notable neuroprotection, suggesting an endogenous protective mechanism. This proof-of-concept work elucidates at the molecular level that by regulating the stereochemical composition of Aβ, its inherent cellular protective antagonistic effect can be activated, providing unprecedented molecular basis for understanding the disease mechanism and subsequent possible clinical research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Tianjin Key Laboratory of Biosensing and Molecular Recognition, Research Center for Analytical Science, Frontiers Science Center for New Organic Matter, Academy for Advanced Interdisciplinary Studies, College of Chemist…
- Key Laboratory of Functional Polymer Materials, Ministry of Education, State Key Laboratory of Medicinal Chemical Biology, Institute of Polymer Chemistry, College of Chemistry, Nankai University, 94 Weijin Road, Tianjin…
- School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
- Haihe Laboratory of Sustainable Chemical Transformations, Tianjin 300192, China.
ORCID-Profile: Jiaxin Zhou, Juan Liu, Zhilin Yu, Zhen Zheng, Gongyu Li
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- National key R&D program of China
- Haihe Laboratory of Sustainable Chemical Transformations
- Open Project Program of the State Key Laboratory of Medical Proteomics
Zitieren
APA
Zhou, J., Liu, J., Liu, X., Ren, L., Yu, Z., Zheng, Z., & Li, G. (2026). Clinically relevant stereochemistry reprograms amyloid proteome for aggregation cross-talk–conferred neuroprotection. Science Advances, 12(13). https://doi.org/10.1126/sciadv.aeb2729
Vancouver
Zhou J, Liu J, Liu X, Ren L, Yu Z, Zheng Z, et al. Clinically relevant stereochemistry reprograms amyloid proteome for aggregation cross-talk–conferred neuroprotection. Science Advances. 2026;12(13). doi:10.1126/sciadv.aeb2729
BibTeX
@article{Zhou2026,
author = {Zhou, Jiaxin and Liu, Juan and Liu, Xilin and Ren, Lixia and Yu, Zhilin and Zheng, Zhen and Li, Gongyu},
title = {Clinically relevant stereochemistry reprograms amyloid proteome for aggregation cross-talk–conferred neuroprotection},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {13},
doi = {10.1126/sciadv.aeb2729}
}
EUVIMED